News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clinical CRO ICRC-Weyer to Boost Drug Safety Services for Investigator Trials


5/31/2013 1:25:24 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PressRelease by ICRC-Weyer GmbH -- The Berlin-based clinical contract research organization (CRO), ICRC-Weyer GmbH, has announced it will boost its drug-safety related Pharmacovigilance Services for Investigator-Initiated Trials amid an increasing demand by trial sponsors.

An increase in the number of requests by trial sponsors for regulatory-compliant drug safety reporting for investigator-initiated trials (IITs) has led the German CRO ICRC-Weyer to amend their services portfolio towards providing these services to large and mid-sized pharmaceutical trial sponsors.

‘A large amount of IITs are oncology trials which generally bear a lot of adverse events (AEs) and serious adverse events (SAEs)’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Many of these events are unrelated to the drug in question. The SAE review process can be a substantial administrative burden for trial sponsors. With our flexible and highly responsive Pharmacovigilance Services we are in a position to take over the entire drug safety reporting for them.’

In addition, ICRC-Weyer is able to handle the reporting of serious adverse drug reactions (ADRs) – adverse events that are directly related to the substance. All events can be transmitted electronically using an E2B*-compliant database.

*Guideline on clinical safety data management by the International Conference on Harmonisation (ICH)

Company information / Profile:

ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and offers services ranging from pre-clinical through to phase IV clinical trials. ICRC-Weyer provides complete turnkey solutions including data management, monitoring and medical review services for all stages of the clinical development process.

ICRC-Weyer has special expertise in Advanced Therapies, CDISC Data Standards and Medical Review.

further Information:

http://icrc-weyer.com

PressContact / Agency:

Dr Ulrike Treichel

ICRC-Weyer GmbH

Boelschestrasse 2, 12587 Berlin, Germany

Phone: +49 30 403937-0

E-mail: ulrike.treichel(at)icrc-weyer.com

www.icrc-weyer.com



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES